DCTs: Opinions, Experiences, And Regulations

We are three years away from when the hype machine surrounding decentralized trials (DCTs) first got revved up, but is interest really slowing? Sure the pros and cons have been debated ad infinitum, but like any polarizing topic, the real result or ultimate change probably lies somewhere in-between traditional site-only trials and “site-less” trials where patients wear and interact with every type of newfangled gadget that tracks and reports back all the data in a perfect little package. Regulatory bodies have weighed in, which means change of some sort is inevitable, and likely, irreversible.